Is Puma Biotechnology Inc (PBYI) overvalued? · P/E 4.3, rev $56.5M
Puma Biotechnology Inc (PBYI) is a biotechnology company listed on US.
This page asks whether Puma Biotechnology Inc (PBYI) looks expensive on cached numbers — not a short thesis.
Latest reported PBYI revenue for 2026-06-30 was $56.5M. Net income was $8.2M. Revenue was up 26.1% from 2026-03-31 to 2026-06-30. PBYI currently screens at market cap $165.3M and trailing P/E 4.3.
PBYI currently screens at market cap $165.3M and trailing P/E 4.3. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next PBYI 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the PBYI stock page for the full model, not this heading.
Not investment advice.